PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and...
Transcript of PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and...
![Page 1: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/1.jpg)
Public Hospitals Can Innovate Too!
Prof. François MachCardiology Department
Geneva University [email protected]
www.cardiology-geneva.ch
State of the art and future of dyslipidemia management
PSCK9 inhibitors: Ready for primetime ?
Swiss Society of Cardiology – Annual MeetingWorkshop 6
Zurich, June 11, 2015
![Page 2: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/2.jpg)
I have received honorarium for advisory board and conferences from:Amgen, AstraZeneca, Daiichi Sankyo, MSD, Pfizer, and Sanofi.
Disclosures
![Page 3: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/3.jpg)
Relationship between LDL-C and CV Event Rate in Primary and Secondary Prevention
Adapted from New Engl J Med 2005;352:1425
![Page 4: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/4.jpg)
LDL-cholesterol levels - Guidelines
ESC/EAS guidelines for the management of dyslipidemias. Eur Heart J 2011;32:1769
![Page 5: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/5.jpg)
Drugs to reduce lipids
• Statins• Ezetimibe• Nicotinic acid• CETP inhibitors (Torcetrapid, Dalcetrapib, Anacetrapib)
• PCSK9 mAb
Proprotein Convertase Subtilisin/Kexin Type 9(PSCK9)
![Page 6: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/6.jpg)
IMPROVE-IT Primary Endpoint — ITTCardiovascular death, MI, documented unstable angina requiring rehospitalization,
coronary revascularization (≥30 days), or stroke
LDL-cholesterol – lower is better
New Engl J Med June 3, 2015
![Page 7: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/7.jpg)
New Engl J Med June 3, 2015
LDL-cholesterol – causality
![Page 8: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/8.jpg)
LDL-cholesterol levels in Switzerland
![Page 9: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/9.jpg)
LDL-cholesterol levels in Switzerland
![Page 10: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/10.jpg)
ASCVD = Atherosclerotic cardiovascular disease
J Am Coll Card 2014;63:2889 Circulation 2014;129:S49
New Guidelines AHA and ACC (end of 2013)
![Page 11: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/11.jpg)
New Engl J Med 2014;370:1422
New Guidelines AHA and ACC (end of 2013)
![Page 12: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/12.jpg)
-> Patients in primary prevention are overtreated-> Patients in secondary prevention are undertreated
-> Compliance worse in fire and forget (OR 2.51), lower event reate in treat to target (HR 0.41)
“Fire and Forget“ strategy worse than “Treat to Target“
Pharmacoepidemiology and Drug Safety 2007;16:385
Overall 45 56
2° Prevention 74 227
fire-and-forgettreat to target
Event rates per 1000 PYFire and forgetTreat to target
AHA/ACC vs ESC guidelines
![Page 13: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/13.jpg)
Adherence to statin
Eur Heart J 2015;36:1012-22
![Page 14: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/14.jpg)
Statin-Associated-Muscle-Symptoms
Eur Heart J 2015;36:1012-22
![Page 15: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/15.jpg)
Meta-analysis of 44 studies, n= 1 978 919; 135 627 CVD events; 94 126 cases of all-cause mortality
Eur Heart J 2013;34:2940
Adherence to statins 0.55
Relative Risk of Death for Adherence> 80% versus < 80%
![Page 16: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/16.jpg)
The Role of PCSK9 in the Regulation of LDL Receptor Expression
![Page 17: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/17.jpg)
Loss of function mutations for PCSK9 in humans are associated with CHD risk reduction
N Engl J Med 2006;354:1264
Study PCSK9
mutation
LDL-C
reduction
CHD risk
reduction
Population
Benn et al.
JACC 2010R46L 12% 46%
Copenhagen City
Heart Study n=10’032
Copenhagen general
population n=26013
Copenhagen ischemic
heart disease n=9654
Cohen et al.
NEJM 2006
R46L
Y142X or
C679X
15%
28%
47%
88%
White patients n=9524
Black patients n=3363
J Am Coll Cardiol 2010;55:2833
![Page 18: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/18.jpg)
New Engl J Med 2006;354:1264
Loss of function mutations for PCSK9 in humans are associated with CHD risk reduction
![Page 19: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/19.jpg)
Impact of Alirocumab on LDL Receptor Expression
![Page 20: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/20.jpg)
Monoclonal antibody
![Page 21: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/21.jpg)
Lancet 2012;380:2007-17
New Engl J Med 2012;367:1891-900
Anti-PCSK9 mAb and LDL-c
![Page 22: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/22.jpg)
Anti-PCSK9 mAb and LDL-c
New Engl J Med 2015;372:1489-99 New Engl J Med 2015;372:1500-9
![Page 23: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/23.jpg)
Primary endpoints: CHD death, Non-fatal MI, Fatal and non-fatal ischemic stroke,UA requiring hospitalisation
Anti-PCSK9 mAb and MACE
ESC Late Clinical Breaking Trial 2014 New Engl J Med 2015;372:1500-9
![Page 24: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/24.jpg)
LDL-cholesterol and CV Risk
Eur Heart J 2015:36:1146-8
![Page 25: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/25.jpg)
Significant risk reduction in patients with lipid polymorphisms
J Am Coll Cardiol 2015, in press
![Page 26: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/26.jpg)
PCSK9 inhibitors in development
Nature Rev Drug Discovery 2012;11:367
![Page 27: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/27.jpg)
0
200
400
600
800
Before During
After
PCSK9 level changes according to physical activity
Differences before and during physical activity were significant (P value = 0.01)
Kamani C, Gencer B et al; Eur J Clin Invest 2015 (in press)
![Page 28: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/28.jpg)
Nature Review Cardiology November 20, 2012
Swiss Med Wkly 2015;145:w14094
PCSK9 inhibitors review
Use and role of monoclonal antibodies and other biologics in preventive cardiology
Baris Gencer, Reijo Laaksonen, Aliki Buhayer, François Mach
Swiss Med Wkly 2015 (in press)
![Page 29: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/29.jpg)
Conclusions
LDL-C causality
Statins as baseline therapy
The earlier and the lower the better
Targets translate evidence to clinical practice
Therapy with PCSK9 antibody will change our practice
![Page 30: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/30.jpg)
Future is almost there…
![Page 31: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/31.jpg)
Thank you
![Page 32: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/32.jpg)
![Page 33: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/33.jpg)
Development of drugs targeting PCSK9
Drug Class Advantages Disadvantages
Small molecular weight
drugs
Oral application
Clearly defined chemical
structure
Off target effects
Drug interactions
Possibly toxic metabolites
Antibodies Long half-life
Simple pharmacokinetics
No kinetic drug
interactions
Local and systemic adverse
reactions
Chemical structure not clearly
defined
Tissue penetration limited
siRNA Long biological half-life Must penetrate cells
Organ targeting usually
necessary
Experience lacking
![Page 34: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/34.jpg)
Loss of function mutations in PCSK9 in humans
• Coding region in 128 subjects with low LDL-C levels sequenced
• 5 missense mutations in PCSK9 gene identified (Y142X and C679X)
• Mutations in approximately 2% Africa Americans and 0.1% European Americans
Nature Genetics 2005;37:161
![Page 35: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/35.jpg)
Family of proprotein convertases (PC)
• Protein activation is frequently
achieved by cleavage of
inactive precursors
• Scientific breakthrough was
the description of the yeast
subtilisin-like serine protease
kexine (SK)
• Important functions in lipid
metabolism, antiviral host
defense, activation of
hormones
• Attractive drug targets
Nature Rev Drug Discovery 2012;11:367
![Page 36: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/36.jpg)
Gain of function mutations in PCSK9 in humans
• 2 families with hypercholesterolemia
(HC92 and HC60)
• The region between D1S197 and
D1S2890 on chromosome 1
contains 41 genes, including
PCSK9
• PCSK9 is related to PCSK1 which is
known to be involved in cholesterol
metabolism
• First demonstration in humans that
PCSK9 is involved in cholesterol
metabolism
Nature Genetics 2003;34:154
![Page 37: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/37.jpg)
Cholesterol metabolism in PCSK9 knock-out mice
• PCSK9-/- mice are compared to wild
type mice at 12 weeks of age
• Both groups were fed normal rodent
chow ad libitum
• Body weight may be slightly higher in
PCSK9-/- mice
• Serum cholesterol is less than 50% in
PCSK9-/- mice
• This is due to a decreased in LDL-C
which is associated with increased
expression of the LDLR
PNAS 2005;102:5374
![Page 38: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/38.jpg)
REGN727 in healthy volunteers
• Randomized single dose-
ascending study with iv (n=40)
and sc application (n=32)
• Intravenous: 0.3 mg/kg, then
1, 3, 6, 12 mg/kg)
• Subcutaneous: 50, 100, 150,
250 mg
• Endpoints: safety, effect on
LDL-C
• Safety: all subjects terminated
study, no TESAR
N Engl J Med 2012;366:1108
![Page 39: PSCK9 inhibitors: Ready for primetime · 2017-01-12 · mAb Levels, PCSK9 and LDL-C-70-60-50-40-30-20-10 0 0 20 40 60 80 100 120 140 160 180 200 0 500 1000 1500 2000 2500 LDL-C hange](https://reader035.fdocuments.us/reader035/viewer/2022070800/5f0251807e708231d403ad6a/html5/thumbnails/39.jpg)
Alirocumab: Dynamic Relationship Between mAb Levels, PCSK9 and LDL-C
-70
-60
-50
-40
-30
-20
-10
0
0
20
40
60
80
100
120
140
160
180
200
0 500 1000 1500 2000 2500
LD
L-C
mean %
change
2 W 4 W
Free PCSK9, total alirocumab concentration and mean % change LDL-C vs time
Total alirocumab
Free PCSK9
LDL-C
Free
/to
tal P
CSK
9 C
on
c. (
ng
/mL)
Tota
l alir
ocu
mab
(ng
/mL)
X 0
.01
Time (hours)
New Engl J Med 2012;366:1108